Applies to perphenazine: oral fixed-combination tablets, oral tablets
Side effects include:
Extrapyramidal reactions (e.g., Parkinson-like symptoms, dystonia, akathisia, tardive dyskinesia), drowsiness, muscular weakness, dry mouth, blurred vision, weight gain, skin reactions, amenorrhea, galactorrhea.
Applies to perphenazine: compounding powder, injectable solution, oral concentrate, oral tablet
Frequency not reported: Extrapyramidal symptoms, opisthotonos, motor restlessness, hyperreflexia, dystonia, slurred speech, akathisia, dyskinesia, parkinsonism, ataxia, drowsiness, sedation, hypnosis, lethargy, cerebral edema, convulsive seizures, hyperactivity
Postmarketing reports: Headaches, choreiform movements of the extremities, orofacial dyskinesia, tardive dyskinesia, disturbances in consciousness, somnolence, stupor, dizziness, tremor, epileptic fits, neuroleptic malignant syndrome (NMS), severe extrapyramidal dysfunction, coma, autonomic disturbances, cerebrospinal fluid protein abnormalities
Convulsive seizures occurred most frequently in patients with EEG abnormalities and/or patients with a history of convulsive seizures.
Drowsiness usually occurred within the first 1 to 2 weeks, with gradual disappearance thereafter.
NMS occurred in patients who took neuroleptic drugs, and was fatal in some cases. NMS was characterized by severe extrapyramidal dysfunction, rigidity, stupor, coma, hyperthermia, and/or autonomic disturbances.
Significant autonomic effects were infrequently reported in patients who received less than 24 mg/day.
Frequency not reported: Pallor, hypertension, change in pulse rate, circulatory collapse, postural hypotension, bradycardia, peripheral edema, shock-like condition (hypotensive effect), reversible and nonspecific ECG changes
Postmarketing reports: Tachycardia, QT prolongation, ventricular arrhythmias, ventricular tachycardia/fibrillation, edema, cardiovascular effects (related to neuroleptic malignant syndrome), hypotension, venous thromboembolism, deep vein thrombosis, cardiac arrest and Torsades de pointes
Tachycardia occurred more commonly with sudden, marked increases in dose.
Frequency not reported: Perspiration, urticaria, erythema, eczema, exfoliative dermatitis, photosensitivity, angioneurotic edema, contact dermatitis, skin pigmentation (in exposed areas)
Postmarketing reports: Photosensitivity, rashes/pruritus, hyperhidrosis
Contact dermatitis occurred in nursing personnel who handled the drug.
Frequency not reported: Nausea, dysphagia, vomiting, diarrhea, obstipation, fecal impaction, parotid swelling, protrusion/discoloration/aching and rounding of tongue,
Postmarketing reports: Oral dryness and altered saliva, adynamic ileus, constipation, other gastrointestinal atonic and hypomotility disorders
Frequency not reported: Trismus, torticollis, retrocollis, aching and numbness of limbs, tonic spasm of masticatory muscles, muscle weakness, prolonged abnormal contractions of muscle groups
Postmarketing reports: Systemic lupus erythematosus (SLE)/SLE-like syndrome, rigidity
Frequency not reported: Oculogyric crisis, myosis, mydriasis, glaucoma, photophobia, epithelial keratopathies
Postmarketing reports: Visual disorders, blurred vision, pigmented/pigmentary retinopathy, star-shaped lenticular opacities, fine particulate matter deposits in the cornea and lens
Frequency not reported: Exacerbation of psychotic symptoms, catatonia/catatonic-like states, paranoid reactions, nocturnal confusion, bizarre dreams, libido changes,
Postmarketing reports: Confusion, agitation, excitement, insomnia
Frequency not reported: Blood dyscrasias, eosinophilia, leukopenia, hemolytic anemia, thrombocytopenic purpura, pancytopenia
Postmarketing reports: Agranulocytosis, transient leukopenia
Frequency not reported: Anorexia, hypoglycemia, polyphagia, increased appetite
Postmarketing reports: Weight gain, hyperglycemia, increased serum cholesterol
Frequency not reported: Throat tightness, asthma, laryngeal edema
Postmarketing reports: Nasal stuffiness, pulmonary embolism
Frequency not reported: Fever/hyperpyrexia, reversed epinephrine effect
Postmarketing reports: Fatigue, body temperature dysregulation, hyperthermia, sudden unexplained death, neonatal drug withdrawal syndrome
Frequency not reported: Syndrome of inappropriate antidiuretic hormone (ADH) secretion, protein bound iodine (PBI) increase not attributable to an increase in thyroxine
Postmarketing reports: Hyperprolactinemia, gynecomastia (males), false positive pregnancy tests
Frequency not reported: Liver damage/biliary stasis, infectious hepatitis
Postmarketing reports: Obstructive jaundice, cholestasis and chronic jaundice
Frequency not reported: Anaphylactoid reactions
Frequency not reported: Glycosuria
Postmarketing reports: Urinary hesitancy/retention/incontinence, amenorrhea, erectile dysfunction, impaired ejaculation, lactation, galactorrhea, moderate breast enlargement (females), bladder paralysis, polyuria, menstruation with decreased bleeding or disturbances in the menstrual cycle
Postmarketing reports: Antinuclear antibodies
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Perphenazine